$1.49
-0.08 (-5.10%)
Open$1.55
Previous Close$1.57
Day High$1.62
Day Low$1.44
52W High$74.30
52W Low$2.20
Volume—
Avg Volume90.6K
Market Cap2.31M
P/E Ratio—
EPS$-342.64
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+145.0% upside
Current
$1.49
$1.49
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 85.90M | 335.8K | 347.3K |
| Net Income | -1,997,253,719 | 43.0K | 52.4K |
| Profit Margin | -2,325.2% | 12.8% | 15.1% |
| EBITDA | -1,849,127,079 | 73.2K | 78.8K |
| Free Cash Flow | — | 45.7K | 64.8K |
| Rev Growth | — | +0.6% | +12.6% |
| Debt/Equity | 0.97 | 0.59 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |